- ICH GCP
- US-Register für klinische Studien
- Klinische Studie NCT01512485
Bioequivalence Study of Clopidogrel Tablets 75 mg Under Fed Conditions
Randomized, Open-label, 2-Way Crossover, Bioequivalence Study of Clopidogrel 75 mg Tablet With Plavix® 75 mg In Healthy Subjects Under Fed Conditions
Studienübersicht
Detaillierte Beschreibung
Studientyp
Einschreibung (Tatsächlich)
Phase
- Phase 1
Kontakte und Standorte
Studienorte
-
-
-
Sainte-Foy (Quebec), Kanada
- Anapharm
-
-
Teilnahmekriterien
Zulassungskriterien
Studienberechtigtes Alter
Akzeptiert gesunde Freiwillige
Studienberechtigte Geschlechter
Beschreibung
Inclusion Criteria:
Subjects enrolled in this study will be members of the community at large. The recruitment advertisements may use various media types (e.g. radio, newspaper, Anapharm Web site, Anapharm volunteers' database). Subjects must meet all of the following criteria to be included in the study:
- Male or female, non-smoker, ≥18 and ≤55 years of age.
- Medically healthy with clinically normal laboratory profile, vital signs and ECG.
- Capable of consent.
- BMI ≥19.0 and <30.0
Exclusion Criteria:
Subjects to whom any of the following applies will be excluded from the study:
- Clinically significant illness or surgery within 4 weeks prior to dosing.
- Any clinically significant abnormality or abnormal laboratory test results found during medical screening.
- Any reason which, in the opinion of the Clinical Sub-.investigator, would prevent the subject from participating in the study.
- Positive test for hepatitis B, hepatitis C, or HIV at screening.
- ECG abnormalities (clinically significant) or vital sign abnormalities (systolic blood pressure lower than 90 or over 140 mmHg, diastolic blood pressure lower than 50 or over 90 mmHg, or• heart rate less than 50 or over J00 bpm) at screening.
- History of significant alcohol abuse or drug abuse within one year prior to the screening visit.
- Regular use of alcohol within six months prior to the screening visit (more than fourteen units of alcohol per week [J Unit = 150 mL of wine, 360 mL of beer, or 45 mL of 40% alcohol]), or positive alcohol breath test at screening.
- Use of soft drugs (such as marijuana) within 3 months prior to the screening visit or hard drugs (such as cocaine, phencyclidine (PCP] and -crack) within 1 year prior to the screening visit or positive urine drug screen at screening.
- History of allergic reactions to clopidogrel or other related drugs.
- Use of any drugs known to induce or inhibit hepatic drug metabolism (examples of inducers: barbiturates, carbamazepine, phenytoin, glucocorticoids, omeprazole; examples of inhibitors: antidepressants (SSRI), cimetidine, diltiazem, macrolides, imidazoles, neuroleptics, verapamil, fIuoroquinolones, antihistamines) within 30 days prior to administration of the study medication.
- Use of an investigational drug or participation in an investigational study within 30 days prior to dosing.
- Clinically significant history or presence of any gastrointestinal pathology (e.g. chronic diarrhea, inflammatory bowel diseases), unresolved gastrointestinal symptoms (e.g. diarrhea, vomiting), liver or kidney disease, or other conditions known to interfere with the absorption, distribution, metabolism, or excretion of the drug.
- Any clinically significant history or presence of neurological, endocrinal, cardiovascular, pulmonary, hematological, immunologic, psychiatric, or metabolic disease.
- Use of prescription medication within 14 days prior to administration of study medication or over-the counter products (including natural food supplements, vitamins, garlic as a supplement) within 7 days prior to administration of study medication, except for topical products without systemic absorption and hormonal contraceptives.
- Difficulty to swallow study medication.
- Use of any tobacco products in the 3 months preceding drug administration.
- Any food allergy, intolerance, restriction or special diet that, in the opinion of the Clinical Sub-Investigator, could contraindicate the subject's participation in this study.
- A depot injection or an implant of any drug (other than hormonal contraceptives) within 3 months prior to administration of study medication.
- Donation of plasma (500 mL) within 7 days prior to drug administration. Donation or loss of whole blood (excluding the volume of blood that will be drawn during the screening procedures of this study) prior to administration of the study medication as follows:
- 50 mL to 499 mL of whole blood within 30 days,
- more than 499 mL of whole blood within 56 days prior to drug administration.
- Positive urine pregnancy test at screening.
- Breast-feeding subject.
- Female subjects of childbearing potential having unprotected sexual intercourse with any non-sterile male partner (i.e. male who has not been sterilized by vasectomy for at least 6 months) within 14 days prior to study drug administration. Acceptable methods of contraception are:
- intra-uterine contraceptive device (placed at least 4 weeks prior to study drug administration;
- condom or diaphragm + spermicide;
- hormonal contraceptives (starting at least 4 weeks prior to study drug administration).
- History or known active pathological bleeding (e.g. peptic ulcer, intracranial hemorrhage).
- Increased risks of bleeding (e.g. frequent nose bleeding, recent trauma, surgery or other pathological condition).
Studienplan
Wie ist die Studie aufgebaut?
Designdetails
- Hauptzweck: Behandlung
- Zuteilung: Zufällig
- Interventionsmodell: Crossover-Aufgabe
- Maskierung: Keine (Offenes Etikett)
Waffen und Interventionen
Teilnehmergruppe / Arm |
Intervention / Behandlung |
---|---|
Experimental: Clopidogrel
Clopidogrel Tabletten 75 mg von Dr. Reddy's Laboratories Limited
|
Clopidogrel Tabletten 75 mg
Andere Namen:
|
Aktiver Komparator: Plavix
Clopidogrel Tablette 75 mg
|
Clopidogrel Tabletten 75 mg
Andere Namen:
|
Was misst die Studie?
Primäre Ergebnismessungen
Ergebnis Maßnahme |
Zeitfenster |
---|---|
Area Under Curve (AUC)
Zeitfenster: predose, 0.250, 0.500, 0.750, 1.00, 1.25, 1.50, 1.75, 2.00, 2.50, 3.00, 4.00, 6.00, 8.00, 12.0, 16.0, and 24.0 hours post-dose
|
predose, 0.250, 0.500, 0.750, 1.00, 1.25, 1.50, 1.75, 2.00, 2.50, 3.00, 4.00, 6.00, 8.00, 12.0, 16.0, and 24.0 hours post-dose
|
Mitarbeiter und Ermittler
Sponsor
Ermittler
- Hauptermittler: Denis Audet, MD, Anapharm
Studienaufzeichnungsdaten
Haupttermine studieren
Studienbeginn
Primärer Abschluss (Tatsächlich)
Studienabschluss (Tatsächlich)
Studienanmeldedaten
Zuerst eingereicht
Zuerst eingereicht, das die QC-Kriterien erfüllt hat
Zuerst gepostet (Schätzen)
Studienaufzeichnungsaktualisierungen
Letztes Update gepostet (Schätzen)
Letztes eingereichtes Update, das die QC-Kriterien erfüllt
Zuletzt verifiziert
Mehr Informationen
Begriffe im Zusammenhang mit dieser Studie
Schlüsselwörter
Zusätzliche relevante MeSH-Bedingungen
- Ernährungsstörungen
- Unterernährung
- Physiologische Wirkungen von Arzneimitteln
- Neurotransmitter-Agenten
- Molekulare Mechanismen der pharmakologischen Wirkung
- Thrombozytenaggregationshemmer
- Purinerge P2Y-Rezeptorantagonisten
- Purinerge P2-Rezeptorantagonisten
- Purinerge Antagonisten
- Purinerge Wirkstoffe
- Clopidogrel
Andere Studien-ID-Nummern
- 60281
Diese Informationen wurden ohne Änderungen direkt von der Website clinicaltrials.gov abgerufen. Wenn Sie Ihre Studiendaten ändern, entfernen oder aktualisieren möchten, wenden Sie sich bitte an register@clinicaltrials.gov. Sobald eine Änderung auf clinicaltrials.gov implementiert wird, wird diese automatisch auch auf unserer Website aktualisiert .
Klinische Studien zur Clopidogrel
-
Korea University Anam HospitalAbgeschlossen
-
Ospedale San DonatoAbgeschlossen
-
Hospital Central San Luis Potosi, MexicoUnbekanntAkutes Koronar-Syndrom
-
University of North Carolina, Chapel HillAbgeschlossen
-
Deutsches Herzzentrum MuenchenBeendetKoronare HerzkrankheitDeutschland
-
University of PecsHungarian Academy of Sciences; KRKAAbgeschlossenKoronare Herzerkrankung | Perkutane Koronarintervention
-
Chinese PLA General HospitalUnbekanntGenotypisierung Geführte individualisierte Behandlung von Clopidogrel und Ticagrelor bei ACS (GI-CT)CLOPIDOGREL, SCHLECHTER STOFFWECHSEL von (Störung)China
-
Ajou University School of MedicineDong-A PharmaceuticalAbgeschlossen
-
Creighton UniversityAbgeschlossen